Irritable Bowel SyndromeNCT02613078
Hypnotherapy vs. Probiotics in Children With IBS and Functional Abdominal Pain
A study testing Gut-Directed Hypnotherapy, Nutritional Supplement and Self-Monitoring in people with Irritable Bowel Syndrome and Functional Abdominal Pain Syndrome, run by University Hospital Tuebingen at 1 site in Germany.
Trial summary
Current study aims to investigate the influence of gut-directed hypnotherapy and probiotic nutritional supplement (SymbioLact B) on gastrointestinal symptoms in children with functional abdominal pain or irritable bowel syndrome compared to self-observation only. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Irritable Bowel Syndrome, Functional Abdominal Pain Syndrome
- What is being tested?
- Gut-Directed Hypnotherapy, Nutritional Supplement and Self-Monitoring
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteGermany
- Study dates
- Mar 2016to Oct 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- age between 6 and 17
- participants should fulfill following criteria for functional abdominal pain (FAP) or irritable bowel syndrome (IBS) according to Rome III Consensus
- medical report from a gastroenterologist about absence of an organic reason for the gastrointestinal complaints
Who cannot join
- organic reason for abdominal pain is diagnosed (e.g. celiac disease, inflammable bowel diseases)
- children fulfill criteria for abdominal migraine
- other acute or chronic disorders of the gastrointestinal, cardiovascular or peripheral nervous system are present
- inability to follow instructions
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
University Clinic
Tübingen, 72076
Marco D Gulewitsch, PhD, 004970712977187, marco-daniel.gulewitsch@uni-tuebingen.de
Paul Enck, PhD, 004970712989118, paul.enck@uni-tuebingen.de
About this study
Official title: Gut-Directed Hypnotherapy vs. Probiotics in Children and Adolescents With Irritable Bowel Syndrome and Functional Abdominal Pain - A Pilot Study
Current study aims to investigate the influence of gut-directed hypnotherapy and probiotic nutritional supplement (SymbioLact B) on gastrointestinal symptoms in children with functional abdominal pain or irritable bowel syndrome compared to self-observation only. The study also includes collection of psychometric data (emotional and behavioral problems, pain coping strategies), data on activity of the autonomous nerve system as measured by heart rate variability and data on stress response (saliva cortisol levels).
Read the detailed description
Children with irritable bowel syndrome (IBS) or other pain-related functional gastrointestinal disorders (FGIDs) such as functional abdominal pain (FAP) represent a considerable part of visits to pediatric practitioners. These disorders do not only decrease the quality of life but also increase the risk of symptom persistence and comorbid mental issues in adulthood. As etiology and pathophysiology of FGIDs are still a matter of research, several approaches of managing of FGIDs are commonly used: dietary interventions, probiotics, drug treatment, psychosocial interventions. While recent meta-analyses showed almost no favorable effects of dietary interventions and drug treatments (5-HT4 receptor agonists, antispasmodic and anti-diarrheal agents, antibiotics) in children with FGIDs, probiotics and psychosocial interventions remain promising regarding effective symptom relief. Several randomized controlled trials (RCT) have shown a beneficial effect of both gut directed hypnosis (GDH) and probiotics. To our knowledge, there are no studies that investigated both types of intervention in comparison to a control group intervention. This study aims to fill this gap.
In a prospective randomized study the investigators aim to obtain preliminary results about the impact of gut-directed hypnotherapy (GDH) modified for self-practicing and probiotic nutritional supplement (NS) on symptoms in children with pain-related FGIDs (IBS and FAP). This is going to be measured by the mean of number of days the children experience no abdominal pain or discomfort. Beside that the investigators plan to obtain data on abdominal pain intensity and duration and about the effects of above mentioned interventions on children's health-related quality of life (KINDL-R), pain-related disability (P-PDI), their coping abilities (PPCI) and behavioural and emotional problems (CBCL). The information obtained from children as well as from parental perspective will allow more extensive models on mechanisms of change.
Beyond psychometric instruments some well-established psychophysiological methods will be used. Assessment of the heart rate variability under mental stress conditions (Parametric Go/No-Go test) and measuring of cortisol awakening response (CAR) are used to study the function of autonomic nerve system and stress-level/tolerance of the study population.
The investigators hypothesize:
- a significant decrease in number of days with pain/discomfort in both intervention groups (GDH, NS) as compared to the control group (active waiting-list control group)
- that both types of intervention lead to an increase of quality of life and decrease of pain duration, intensity and pain-related disability as compared to the control group.
- a decrease of physiological stress parameters (as measured by heart rate variability [HRV] analysis, cortisol awakening response [CAR]) in both intervention groups as compared to the control group, but more prominent in GDH group.
The data of this pilot study will be used for further projects where the most promising intervention and research parameters will be investigated more detailed in a larger sample.
Current study is regarded as a pilot and is conducted in order to obtain information about the efficacy of GDH and probiotic intervention in children with IBS or FAP as compared to reference group. Based on our previous studies and data of literature the investigators expect to see moderate effect power of the primary outcome measure (η²~.06). In order to detect a 50% improvement of symptoms during 4 week treatment with 80% power, assuming α=.05 and using a 2 x 3 repeated measure design for the main analysis, 51 participants should be included in the study. Taking into account possible dropouts the investigators plan to recruit 60 children (20 children per group).
Short description of study protocol: Parents that are interested in the study after a first contact with the investigators will receive detailed informations about the study and a short anamnestic questionnaire. After returning it they will be invited together with their children for the diagnostic appointment ("Visit I"). Inclusion into the study will be made based on the results of anamnestic interview as well as based on the reports from the responsible gastroenterologist regarding exclusion of other possible reason for the symptoms (including organic disorder, e.g. Celiac disease). Participants and their parents will also receive all necessary information about goals of the study and methods used in the study as well as about possible health risks from applied interventions. Informed consent is to be signed prior inclusion in the study. After inclusion, children and parents will be asked not to change any currently used medications or to undertake another treatment, as well as not to change usual habits until the end of the follow-up period.
Participants will be filling in diaries that will question about their symptoms once a day.
During the first two weeks ("run-in period") participants will only be keeping their symptom diaries. This data will be used in later analysis as "baseline" data for comparison with any changes that will occur due to intervention. The week three and four are regarded as "wash-out period": participants will be instructed to stop answering questions in diaries. The investigators hypothesize that this will reduce the effect of self-monitoring when the treatment starts.
At the end of week four, children will be randomized into one of three groups: based on computer generated table of random numbers each participant will be allocated either to a group practicing a gut-directed hypnosis or receiving a probiotic for the next four weeks (SymbioLact B) or reference group (only symptom diaries). Participants are randomized with an aspect ratio 1:1:1. Children will continue to keep the symptom diaries for another two weeks (week 9 and 10) and will return them to the investigators during "Visit II" at the end of 10th week.
Visits I and II will also be used to collect psychometric data from children and their parents as well as psychophysiological measures (HRV). Saliva samples should be collected at home: participants will be provided with appropriate collection tubes as well as with detailed instructions on how to collect, store and deliver samples to the investigation site. Baseline saliva samples should be collected inside the first week and during week 10 (in a morning before Visit II).
For ethical reasons, a second intervention can be chosen freely by the family after the follow-up period.
Risks of the study: A systematic review and meta-analysis of randomized clinical trials about the effects of probiotic in children with pain-related FGID as well as RCTs report seldom or no adverse effects from probiotics. If appeared - most often in a form of gastroenteritis and vomiting - the adverse effects were comparable to those in a placebo group. Based on previous studies of our group we expect no adverse events from gut directed hypnosis. All adverse events in any group will be documented and reported.
- Being tested
- Gut-Directed Hypnotherapy, Nutritional Supplement, Self-Monitoring
- Keywords
- Children, Functional Abdominal Pain Syndrome, Irritable Bowel Syndrome, Gut-Directed Hypnotherapy, Probiotic
- Medical subject headings
- Irritable Bowel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gut-Directed HypnotherapyBehavioural
Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
Nutritional SupplementDietary supplement
Also called SymbioLact B
SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
Self-MonitoringBehavioural
Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
| Study group | Role | What they receive |
|---|---|---|
| Gut-Directed Hypnotherapy (GDH) | Experimental | Gut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week) Receives: Behavioral: Gut-Directed Hypnotherapy; Behavioral: Self-Monitoring |
| Probiotic (NS) | Experimental | Nutritional supplement SymbioLact B once a day diluted in water or tea Receives: Dietary Supplement: Nutritional Supplement; Behavioral: Self-Monitoring |
| Active Controls (AC) | Active comparator | AC group keeps a symptom dairy (self-monitoring) Receives: Behavioral: Self-Monitoring |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in number of days with pain/discomfort
Measured: baseline, at week 10 and at 3 months follow-up
Secondary outcomes (10)
Change in parental report on gastrointestinal symptoms (Abdominal Pain Index (API))
Measured: baseline, at week 10 and at 3 months follow-up
Change in pain related disability (Pediatric Pain Disability Index (P-PDI))
Measured: baseline, at week 10 and at 3 months follow-up
Change in somatic complaints (Children's Somatization Inventory (CSI))
Measured: baseline, at week 10 and at 3 months follow-up
Change in health-related quality of life (KINDL-R Questionnaire)
The KINDL-R is a generic instrument for assessing Health-Related Quality of Life in children and adolescents
Measured: baseline, at week 10 and at 3 months follow-up
Change in pain-related coping (Pediatric Pain Coping Inventory (PPCI))
Measured: baseline, at week 10 and at 3 months follow-up
Change in emotional and behavioural problems (Child Behaviour Checklist (CBCL))
Measured: baseline, at week 10 and at 3 months follow-up
Change in heart rate variability
Measured: baseline and at week 10
Change in cortisol awakening response (amount of cortisol in saliva, nmol/l)
Measured: baseline and at week 10
Change in self-reported pain intensity (Visual Analog Scale)
Measured: baseline, at week 10 and at 3 months follow-up
Change in self-reported pain duration (hours per day)
Measured: baseline, at week 10 and at 3 months follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2015 (estimated)
- Study startMar 2016
- Primary completionApr 2017 (estimated)
- Study completionOct 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Irritable Bowel SyndromeStudies of the same condition, open and under way.
- More trials run by University Hospital TuebingenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Tuebingen
- Sponsor type
- University, hospital or other
- Collaborators
- SymbioPharm GmbH
- Responsible party
- Sponsor
- Investigators
- Marco D Gulewitsch, PhD, Principal investigator, Eberhard Karls University, Tübingen, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02613078
- Sponsor's protocol ID
- MDG 082015
- Status last verified
- Feb 2016
- First submitted
- 23 Oct 2015
- Last updated
- 3 Mar 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol. 2005 Aug;100(8):1868-75. doi: 10.1111/j.1572-0241.2005.41893.x.
PubMed 16086724Schlarb AA, Gulewitsch MD, Bock Genannt Kasten I, Enck P, Hautzinger M. Recurrent abdominal pain in children and adolescents - a survey among paediatricians. Psychosoc Med. 2011 Mar 28;8:Doc02. doi: 10.3205/psm000071.
PubMed 21468324Chitkara DK, van Tilburg MA, Blois-Martin N, Whitehead WE. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol. 2008 Mar;103(3):765-74; quiz 775. doi: 10.1111/j.1572-0241.2007.01722.x. Epub 2008 Jan 2.
PubMed 18177446Campo JV, Di Lorenzo C, Chiappetta L, Bridge J, Colborn DK, Gartner JC Jr, Gaffney P, Kocoshis S, Brent D. Adult outcomes of pediatric recurrent abdominal pain: do they just grow out of it? Pediatrics. 2001 Jul;108(1):E1. doi: 10.1542/peds.108.1.e1.
PubMed 11433080Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006 Jul 15;24(2):183-205. doi: 10.1111/j.1365-2036.2006.02938.x.
PubMed 16842448Sandhu BK, Paul SP. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World J Gastroenterol. 2014 May 28;20(20):6013-23. doi: 10.3748/wjg.v20.i20.6013.
PubMed 24876724Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr. 2014 Apr;103(4):365-72. doi: 10.1111/apa.12513. Epub 2014 Jan 7.
PubMed 24236577Tabbers MM, Chmielewska A, Roseboom MG, Crastes N, Perrin C, Reitsma JB, Norbruis O, Szajewska H, Benninga MA. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. 2011 Jun;127(6):e1392-9. doi: 10.1542/peds.2010-2590. Epub 2011 May 23.
PubMed 21606153Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr. 2005 Mar;146(3):364-9. doi: 10.1016/j.jpeds.2004.10.022.
PubMed 15756221Gulewitsch MD, Muller J, Hautzinger M, Schlarb AA. Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and irritable bowel syndrome in childhood: a randomized controlled trial. Eur J Pediatr. 2013 Aug;172(8):1043-51. doi: 10.1007/s00431-013-1990-y. Epub 2013 Apr 9.
PubMed 23568514
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Gut-Directed Hypnotherapy vs. Probiotics in Children and Adolescents With Irritable Bowel Syndrome and Functional Abdominal Pain - A Pilot Study
- ClinicalTrials.gov ID
- NCT02613078
- Acronym / sponsor ID
- MDG 082015
- Keywords
- Children, Functional Abdominal Pain Syndrome, Irritable Bowel Syndrome, Gut-Directed Hypnotherapy, Probiotic
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University Hospital TuebingenUniversity, hospital or other
- Collaborators
- SymbioPharm GmbH
- Study start
- Mar 2016
- Primary completion
- Apr 2017 (estimated)
- Study completion
- Oct 2017 (estimated)
- First posted
- 24 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Current study aims to investigate the influence of gut-directed hypnotherapy and probiotic nutritional supplement (SymbioLact B) on gastrointestinal symptoms in children with functional abdominal pain or irritable bowel syndrome compared to self-observation only. The study also includes collection of psychometric data (emotional and behavioral problems, pain coping strategies), data on activity of the autonomous nerve system as measured by heart rate variability and data on stress response (saliva cortisol levels).
Detailed description
Children with irritable bowel syndrome (IBS) or other pain-related functional gastrointestinal disorders (FGIDs) such as functional abdominal pain (FAP) represent a considerable part of visits to pediatric practitioners. These disorders do not only decrease the quality of life but also increase the risk of symptom persistence and comorbid mental issues in adulthood. As etiology and pathophysiology of FGIDs are still a matter of research, several approaches of managing of FGIDs are commonly used: dietary interventions, probiotics, drug treatment, psychosocial interventions. While recent meta-analyses showed almost no favorable effects of dietary interventions and drug treatments (5-HT4 receptor agonists, antispasmodic and anti-diarrheal agents, antibiotics) in children with FGIDs, probiotics and psychosocial interventions remain promising regarding effective symptom relief. Several randomized controlled trials (RCT) have shown a beneficial effect of both gut directed hypnosis (GDH) and probiotics. To our knowledge, there are no studies that investigated both types of intervention in comparison to a control group intervention. This study aims to fill this gap.
In a prospective randomized study the investigators aim to obtain preliminary results about the impact of gut-directed hypnotherapy (GDH) modified for self-practicing and probiotic nutritional supplement (NS) on symptoms in children with pain-related FGIDs (IBS and FAP). This is going to be measured by the mean of number of days the children experience no abdominal pain or discomfort. Beside that the investigators plan to obtain data on abdominal pain intensity and duration and about the effects of above mentioned interventions on children's health-related quality of life (KINDL-R), pain-related disability (P-PDI), their coping abilities (PPCI) and behavioural and emotional problems (CBCL). The information obtained from children as well as from parental perspective will allow more extensive models on mechanisms of change.
Beyond psychometric instruments some well-established psychophysiological methods will be used. Assessment of the heart rate variability under mental stress conditions (Parametric Go/No-Go test) and measuring of cortisol awakening response (CAR) are used to study the function of autonomic nerve system and stress-level/tolerance of the study population.
The investigators hypothesize:
- a significant decrease in number of days with pain/discomfort in both intervention groups (GDH, NS) as compared to the control group (active waiting-list control group)
- that both types of intervention lead to an increase of quality of life and decrease of pain duration, intensity and pain-related disability as compared to the control group.
- a decrease of physiological stress parameters (as measured by heart rate variability [HRV] analysis, cortisol awakening response [CAR]) in both intervention groups as compared to the control group, but more prominent in GDH group.
The data of this pilot study will be used for further projects where the most promising intervention and research parameters will be investigated more detailed in a larger sample.
Current study is regarded as a pilot and is conducted in order to obtain information about the efficacy of GDH and probiotic intervention in children with IBS or FAP as compared to reference group. Based on our previous studies and data of literature the investigators expect to see moderate effect power of the primary outcome measure (η²~.06). In order to detect a 50% improvement of symptoms during 4 week treatment with 80% power, assuming α=.05 and using a 2 x 3 repeated measure design for the main analysis, 51 participants should be included in the study. Taking into account possible dropouts the investigators plan to recruit 60 children (20 children per group).
Short description of study protocol: Parents that are interested in the study after a first contact with the investigators will receive detailed informations about the study and a short anamnestic questionnaire. After returning it they will be invited together with their children for the diagnostic appointment ("Visit I"). Inclusion into the study will be made based on the results of anamnestic interview as well as based on the reports from the responsible gastroenterologist regarding exclusion of other possible reason for the symptoms (including organic disorder, e.g. Celiac disease). Participants and their parents will also receive all necessary information about goals of the study and methods used in the study as well as about possible health risks from applied interventions. Informed consent is to be signed prior inclusion in the study. After inclusion, children and parents will be asked not to change any currently used medications or to undertake another treatment, as well as not to change usual habits until the end of the follow-up period.
Participants will be filling in diaries that will question about their symptoms once a day.
During the first two weeks ("run-in period") participants will only be keeping their symptom diaries. This data will be used in later analysis as "baseline" data for comparison with any changes that will occur due to intervention. The week three and four are regarded as "wash-out period": participants will be instructed to stop answering questions in diaries. The investigators hypothesize that this will reduce the effect of self-monitoring when the treatment starts.
At the end of week four, children will be randomized into one of three groups: based on computer generated table of random numbers each participant will be allocated either to a group practicing a gut-directed hypnosis or receiving a probiotic for the next four weeks (SymbioLact B) or reference group (only symptom diaries). Participants are randomized with an aspect ratio 1:1:1. Children will continue to keep the symptom diaries for another two weeks (week 9 and 10) and will return them to the investigators during "Visit II" at the end of 10th week.
Visits I and II will also be used to collect psychometric data from children and their parents as well as psychophysiological measures (HRV). Saliva samples should be collected at home: participants will be provided with appropriate collection tubes as well as with detailed instructions on how to collect, store and deliver samples to the investigation site. Baseline saliva samples should be collected inside the first week and during week 10 (in a morning before Visit II).
For ethical reasons, a second intervention can be chosen freely by the family after the follow-up period.
Risks of the study: A systematic review and meta-analysis of randomized clinical trials about the effects of probiotic in children with pain-related FGID as well as RCTs report seldom or no adverse effects from probiotics. If appeared - most often in a form of gastroenteritis and vomiting - the adverse effects were comparable to those in a placebo group. Based on previous studies of our group we expect no adverse events from gut directed hypnosis. All adverse events in any group will be documented and reported.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Gut-Directed Hypnotherapy (GDH) | Experimental | Behavioral: Gut-Directed Hypnotherapy, Behavioral: Self-MonitoringGut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week) |
| Probiotic (NS) | Experimental | Dietary Supplement: Nutritional Supplement, Behavioral: Self-MonitoringNutritional supplement SymbioLact B once a day diluted in water or tea |
| Active Controls (AC) | Active comparator | Behavioral: Self-MonitoringAC group keeps a symptom dairy (self-monitoring) |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- age between 6 and 17
- participants should fulfill following criteria for functional abdominal pain (FAP) or irritable bowel syndrome (IBS) according to Rome III Consensus
- medical report from a gastroenterologist about absence of an organic reason for the gastrointestinal complaints
Key exclusion criteria (4 listed)
- organic reason for abdominal pain is diagnosed (e.g. celiac disease, inflammable bowel diseases)
- children fulfill criteria for abdominal migraine
- other acute or chronic disorders of the gastrointestinal, cardiovascular or peripheral nervous system are present
- inability to follow instructions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gut-Directed HypnotherapyHypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks | Behavioural | Gut-Directed Hypnotherapy (GDH) |
| Nutritional SupplementAlso: SymbioLact BSymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks | Dietary supplement | Probiotic (NS) |
| Self-MonitoringUse of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening) | Behavioural | Active Controls (AC), Gut-Directed Hypnotherapy (GDH), Probiotic (NS) |
Primary outcome
Change in number of days with pain/discomfort
Time frame: baseline, at week 10 and at 3 months follow-up
10 secondary outcomes
Change in parental report on gastrointestinal symptoms (Abdominal Pain Index (API))
Time frame: baseline, at week 10 and at 3 months follow-up
Change in pain related disability (Pediatric Pain Disability Index (P-PDI))
Time frame: baseline, at week 10 and at 3 months follow-up
Change in somatic complaints (Children's Somatization Inventory (CSI))
Time frame: baseline, at week 10 and at 3 months follow-up
Change in health-related quality of life (KINDL-R Questionnaire)
Time frame: baseline, at week 10 and at 3 months follow-up
Change in pain-related coping (Pediatric Pain Coping Inventory (PPCI))
Time frame: baseline, at week 10 and at 3 months follow-up
Change in emotional and behavioural problems (Child Behaviour Checklist (CBCL))
Time frame: baseline, at week 10 and at 3 months follow-up
Change in heart rate variability
Time frame: baseline and at week 10
Change in cortisol awakening response (amount of cortisol in saliva, nmol/l)
Time frame: baseline and at week 10
Change in self-reported pain intensity (Visual Analog Scale)
Time frame: baseline, at week 10 and at 3 months follow-up
Change in self-reported pain duration (hours per day)
Time frame: baseline, at week 10 and at 3 months follow-up
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2016.
- Background: PubMed 16086724Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol. 2005 Aug;100(8):1868-75. doi: 10.1111/j.1572-0241.2005.41893.x.
- Background: PubMed 21468324Schlarb AA, Gulewitsch MD, Bock Genannt Kasten I, Enck P, Hautzinger M. Recurrent abdominal pain in children and adolescents - a survey among paediatricians. Psychosoc Med. 2011 Mar 28;8:Doc02. doi: 10.3205/psm000071.
- Background: PubMed 18177446Chitkara DK, van Tilburg MA, Blois-Martin N, Whitehead WE. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol. 2008 Mar;103(3):765-74; quiz 775. doi: 10.1111/j.1572-0241.2007.01722.x. Epub 2008 Jan 2.
- Background: PubMed 11433080Campo JV, Di Lorenzo C, Chiappetta L, Bridge J, Colborn DK, Gartner JC Jr, Gaffney P, Kocoshis S, Brent D. Adult outcomes of pediatric recurrent abdominal pain: do they just grow out of it? Pediatrics. 2001 Jul;108(1):E1. doi: 10.1542/peds.108.1.e1.
- Background: PubMed 16842448Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006 Jul 15;24(2):183-205. doi: 10.1111/j.1365-2036.2006.02938.x.
- Background: PubMed 24876724Sandhu BK, Paul SP. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World J Gastroenterol. 2014 May 28;20(20):6013-23. doi: 10.3748/wjg.v20.i20.6013.
- Background: PubMed 24236577Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr. 2014 Apr;103(4):365-72. doi: 10.1111/apa.12513. Epub 2014 Jan 7.
- Background: PubMed 21606153Tabbers MM, Chmielewska A, Roseboom MG, Crastes N, Perrin C, Reitsma JB, Norbruis O, Szajewska H, Benninga MA. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. 2011 Jun;127(6):e1392-9. doi: 10.1542/peds.2010-2590. Epub 2011 May 23.
- Background: PubMed 15756221Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr. 2005 Mar;146(3):364-9. doi: 10.1016/j.jpeds.2004.10.022.
- Background: PubMed 23568514Gulewitsch MD, Muller J, Hautzinger M, Schlarb AA. Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and irritable bowel syndrome in childhood: a randomized controlled trial. Eur J Pediatr. 2013 Aug;172(8):1043-51. doi: 10.1007/s00431-013-1990-y. Epub 2013 Apr 9.
Related trials for Irritable Bowel Syndrome
RecruitingObservational study
Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and the Gut-Skin Axis
IBS (Irritable Bowel Syndrome), Rosacea
Recruiting
Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
Irritable Bowel Syndrome
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Irritable Bowel Syndrome, Diarrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marco D Gulewitsch, PhD principal investigator
Eberhard Karls University, Tübingen, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Gut-Directed Hypnotherapy, Nutritional Supplement and Self-Monitoring in people with Irritable Bowel Syndrome and Functional Abdominal Pain Syndrome, run by University Hospital Tuebingen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Marco D Gulewitsch, PhD (+4970712977187, marco-daniel.gulewitsch@uni-tuebingen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in number of days with pain/discomfort (time frame: baseline, at week 10 and at 3 months follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02613078, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2016.